This gene encodes a member of the receptor tyrosine kinase family of proteins and the product of the proto-oncogene MET. The encoded preproprotein is proteolytically processed to generate alpha and beta subunits that are linked via disulfide bonds to form the mature receptor. Further processing of the beta subunit results in the formation of the M10 peptide, which has been show... See more...

Aliases for MET Gene

Aliases for MET Gene

  • MET Proto-Oncogene, Receptor Tyrosine Kinase 2 3 5
  • Hepatocyte Growth Factor Receptor 2 3 4
  • Tyrosine-Protein Kinase Met 3 4
  • Scatter Factor Receptor 3 4
  • Proto-Oncogene C-Met 3 4
  • HGF/SF Receptor 3 4
  • HGF Receptor 3 4
  • SF Receptor 3 4
  • EC 2.7.10.1 4 54
  • Met Proto-Oncogene 2
  • EC 2.7.10 54
  • DFNB97 3
  • AUTS9 3
  • RCCP2 3
  • C-Met 3
  • HGFR 3

External Ids for MET Gene

Previous GeneCards Identifiers for MET Gene

  • GC07P114790
  • GC07P115853
  • GC07P115866
  • GC07P115906
  • GC07P116099
  • GC07P116312
  • GC07P110678

Summaries for MET Gene

Entrez Gene Summary for MET Gene

  • This gene encodes a member of the receptor tyrosine kinase family of proteins and the product of the proto-oncogene MET. The encoded preproprotein is proteolytically processed to generate alpha and beta subunits that are linked via disulfide bonds to form the mature receptor. Further processing of the beta subunit results in the formation of the M10 peptide, which has been shown to reduce lung fibrosis. Binding of its ligand, hepatocyte growth factor, induces dimerization and activation of the receptor, which plays a role in cellular survival, embryogenesis, and cellular migration and invasion. Mutations in this gene are associated with papillary renal cell carcinoma, hepatocellular carcinoma, and various head and neck cancers. Amplification and overexpression of this gene are also associated with multiple human cancers. [provided by RefSeq, May 2016]

CIViC Summary for MET Gene

  • Mesenchymal Epithelial Transition MET is a prototypical receptor tyrosine kinase. Its ligand is Hepatocyte Growth Factor (HGF). MET alterations are drivers of human cancer. Amplification and resulting overexpression has been reported in several cancers, and make the receptor's activity independent of HGF. Gene fusions also decouple kinase activity from the cell membrane and render it constitutively active. Finally, exclusion of the juxtamembrane (JM) domain of the kinase by "skipping" of exon 14 activates the kinase.

GeneCards Summary for MET Gene

MET (MET Proto-Oncogene, Receptor Tyrosine Kinase) is a Protein Coding gene. Diseases associated with MET include Renal Cell Carcinoma, Papillary, 1 and Deafness, Autosomal Recessive 97. Among its related pathways are PI3K/AKT activation and RET signaling. Gene Ontology (GO) annotations related to this gene include transferase activity, transferring phosphorus-containing groups and protein tyrosine kinase activity. An important paralog of this gene is MST1R.

UniProtKB/Swiss-Prot Summary for MET Gene

  • Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During embryonic development, MET signaling plays a role in gastrulation, development and migration of muscles and neuronal precursors, angiogenesis and kidney formation. In adults, participates in wound healing as well as organ regeneration and tissue remodeling. Promotes also differentiation and proliferation of hematopoietic cells. May regulate cortical bone osteogenesis (By similarity).
  • (Microbial infection) Acts as a receptor for Listeria monocytogenes internalin InlB, mediating entry of the pathogen into cells.

Tocris Summary for MET Gene

  • The MET receptor, also known as hepatocyte growth factor receptor (HGFR), is a proto-oncogenic receptor tyrosine kinase. The endogenous ligand for MET is hepatocyte growth factor/scatter factor (HGF), a disulfide-linked heterodimeric molecule.

Gene Wiki entry for MET Gene

Additional gene information for MET Gene

No data available for PharmGKB "VIP" Summary , Rfam classification and piRNA Summary for MET Gene

Genomics for MET Gene

GeneHancer (GH) Regulatory Elements for MET Gene

Promoters and enhancers for MET Gene
GeneHancer (GH) Identifier GH Type GH
Score
GH Sources Gene Association Score Total Score TSS distance (kb) Number of Genes Away Size (kb) Transcription Factor
Binding Sites
Gene Targets
GH07J116670 Promoter/Enhancer 2.4 EPDnew FANTOM5 Ensembl ENCODE CraniofacialAtlas dbSUPER 758.2 +1.0 976 5.9 SIN3A CTCF RBPJ POLR2A USF2 NR2F6 MIXL1 ZNF362 HLF L3MBTL2 MET TES ENSG00000243243 CAV2 ST7 piR-61532-304
GH07J116775 Enhancer 1.2 Ensembl ENCODE dbSUPER 34.3 +107.5 107505 8.6 TCF7L2 ZNF217 CREB1 RAD21 ZNF121 MNT ZBTB33 SP1 MAFK SP7 MET CAPZA2 ENSG00000235427 ENSG00000243220 CFTR lnc-WNT2-5
GH07J116715 Enhancer 1.4 FANTOM5 Ensembl ENCODE dbSUPER 25.9 +44.3 44300 2.6 SIN3A POLR2A SP7 ZSCAN21 PRDM1 PRDM10 ZNF639 SMARCC1 SMARCC2 ZNF512 MET piR-61532-304
GH07J116732 Enhancer 1.1 Ensembl ENCODE dbSUPER 30 +63.8 63841 6.7 FOXA1 NR2F6 MIXL1 RAD21 RERE ELF3 SP1 CEBPG PPARG CEBPA lnc-CAPZA2-3 MET CAPZA2 RF00066-177
GH07J116800 Enhancer 1.5 Ensembl ENCODE CraniofacialAtlas dbSUPER 19.3 +131.3 131274 7.1 FOXK2 CTCF GATA3 RBPJ POLR2A TCF7L2 CTBP1 USF2 NR2F1 NR2F6 MET CAPZA2 lnc-WNT2-5
- Elite GeneHancer and/or Elite GeneHancer-gene association Download GeneHancer data from 2017 publication | Request up-to-date GeneHancer data (full dataset)

GeneHancers around MET on UCSC Golden Path with GeneCards custom track

Top Transcription factor binding sites by QIAGEN in the MET gene promoter:
  • AP-1
  • ATF-2
  • c-Jun
  • FOXD3
  • N-Myc
  • NF-1
  • p300
  • p53
  • S8
  • Sp1

Genomic Locations for MET Gene

Genomic Locations for MET Gene
chr7:116,672,196-116,798,386
(GRCh38/hg38)
Size:
126,191 bases
Orientation:
Plus strand
chr7:116,312,444-116,438,440
(GRCh37/hg19)
Size:
125,997 bases
Orientation:
Plus strand

Genomic View for MET Gene

Genes around MET on UCSC Golden Path with GeneCards custom track

Cytogenetic band:
MET Gene in genomic location: bands according to Ensembl, locations according to GeneLoc (and/or Entrez Gene and/or Ensembl if different)
Genomic Location for MET Gene
GeneLoc Logo Genomic Neighborhood Exon StructureGene Density

RefSeq DNA sequence for MET Gene

Proteins for MET Gene

  • Protein details for MET Gene (UniProtKB/Swiss-Prot)

    Protein Symbol:
    P08581-MET_HUMAN
    Recommended name:
    Hepatocyte growth factor receptor
    Protein Accession:
    P08581
    Secondary Accessions:
    • A1L467
    • B5A932
    • E7EQ94
    • O60366
    • Q12875
    • Q9UDX7
    • Q9UPL8

    Protein attributes for MET Gene

    Size:
    1390 amino acids
    Molecular mass:
    155541 Da
    Quaternary structure:
    • Heterodimer made of an alpha chain (50 kDa) and a beta chain (145 kDa) which are disulfide linked. Binds PLXNB1. Interacts when phosphorylated with downstream effectors including STAT3, PIK3R1, SRC, PCLG1, GRB2 and GAB1. Interacts with SPSB1, SPSB2 and SPSB4 (By similarity). Interacts with INPP5D/SHIP1. When phosphorylated at Tyr-1356, interacts with INPPL1/SHIP2. Interacts with RANBP9 and RANBP10, as well as SPSB1, SPSB2, SPSB3 and SPSB4. SPSB1 binding occurs in the presence and in the absence of HGF, however HGF treatment has a positive effect on this interaction. Interacts with MUC20; prevents interaction with GRB2 and suppresses hepatocyte growth factor-induced cell proliferation. Interacts with GRB10. Interacts with PTPN1 and PTPN2. Interacts with LECT2; this interaction may have an antagonistic effect on receptor activation (PubMed:27334921). Interacts with HSP90AA1 and HSP90AB1; the interaction suppresses MET kinase activity (PubMed:26517842).
    • (Microbial infection) Interacts via extracytoplasmic residues 25-656 with L.monocytogenes InlB; MET can bind HGF, its endogenous ligand, and InlB simultaneously (PubMed:11081636, PubMed:17662939). InlB probably dimerizes upon binding to MET, which encourages subsequent dimerization of MET (Probable).

    Three dimensional structures from OCA and Proteopedia for MET Gene

    Alternative splice isoforms for MET Gene

    UniProtKB/Swiss-Prot:

neXtProt entry for MET Gene

Selected DME Specific Peptides for MET Gene

P08581:
  • IGRGHFGCVYHGTLLDND
  • KANLSGG
  • KSEMNVNM
  • SPILTSGDSD
  • VDTYYDDQLISCGSV
  • FLWLKKRKQ
  • DNINMAL
  • SVRRLKET
  • LHEHHIFLGATNYIYVLNEEDLQKVAE
  • SGGVWKDN
  • RDLAARN
  • SCTLTLSEST
  • APLEGGT
  • GNENVLEIKGNDIDPEAVKGEVLKVGNKSCE
  • LVQAVQHVVIGP
  • EYKTGPV
  • IDPEAVKGEVLKVGNKSCENIH
  • LDSHPVS
  • MNVNMKYQLPNFTA
  • VLLGNESC
  • KGDLTIANLGTSEGRF
  • STVLGKVIVQPDQN
  • AVLCTVP
  • KPGAQLA
  • LIGFGLQVA
  • LPVKWMA
  • GFMFLTDQSY
  • SILECYTP
  • NSSYFPDH
  • KDRFINFFVGNTI
  • GVFAQSKPDSAEPM
  • ELVSRISAIFS
  • CPDCVVSALG
  • FVQCGWC
  • HVVIGPSSLIVHFNEVIGRGHFGCVYHGTLLD
  • LGKVIVQPDQNFTGLI
  • GECKEAL
  • DEYRTEFTTA
  • TVACQHRS
  • PDQNFTGLIAGV
  • EGSPLVVLPYMKHGDLRNFIRNE
  • RGTCQRH
  • HFQSCSQCL
  • ELNIEWKQA
  • CVAPYPSLLSS
  • FIYFLTVQ
  • DLLKLNS
  • PVITSISP
  • YREDPIV
  • RPSFSELVS
  • YQLPNFTAET
  • IPLNGLGC
  • FHTRIIRFCS
  • CAFPIKY
  • GGTLLTL
  • SKYFDLIYVH
  • QPEYCPD
  • LKCTVGPA
  • DDILFGVFAQSKPDSAEP
  • FTVKVADFGLAR
  • HGTTQYSTFSYVDP
  • KQIKDLGSELVRYD
  • SGTWTQQICLPAIYKVFP
  • KLKIDLA
  • NTLKCTVG
  • KSDVWSFG
  • HTPHLDRLVSARS
  • EVMLKCWHP
  • CGWDFGF
  • FSYREDP
  • DCSSKAN
  • FLTDQSYIDVLP
  • MKDFSHPNV
  • KCVRSEEC
  • NNKFDLKKT
  • YVHNPVF
  • CRQVQYPLTD
  • FFNKIVNKNNV
  • EMPLECILTEKR
  • LECYTPAQ
  • FRDSYPIKY
  • EDPIVYEIHPTKSFISGGSTITG
  • TGPVLEHP
  • DLFMGQF
  • DKEYYSV
  • WMALESL
  • GKNLNSVS
  • EVFNILQAAYV
  • FVHRDLA
  • TCTLKSVS
  • LHSISVRR
  • VLLTSISTF
  • FEKPVMIS

Post-translational modifications for MET Gene

  • Autophosphorylated in response to ligand binding on Tyr-1234 and Tyr-1235 in the kinase domain leading to further phosphorylation of Tyr-1349 and Tyr-1356 in the C-terminal multifunctional docking site. Dephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365. Dephosphorylated by PTPN1 and PTPN2.
  • Ubiquitinated. Ubiquitination by CBL regulates MET endocytosis, resulting in decreasing plasma membrane receptor abundance, and in endosomal degradation and/or recycling of internalized receptors.
  • (Microbial infection) Tyrosine phosphorylation is stimulated by L.monocytogenes InlB. Tyrosine phosphorylation is maximal 10-20 minutes after treatment with InlB and disappears by 60 minutes. The phosphorylated residues were not identified.
  • Glycosylation at Asn45, Asn106, Asn149, Asn202, Asn399, Asn405, Asn607, Asn635, Asn785, Asn879, Asn930, Asn998, and Asn1171
  • Ubiquitination at Lys962
  • Modification sites at PhosphoSitePlus
  • Glycosylation from GlyConnect
    • MET_HUMAN (680)

Antibody Products

Protein Products

Domains & Families for MET Gene

Gene Families for MET Gene

HGNC:
IUPHAR :
Human Protein Atlas (HPA):
  • Cancer-related genes
  • Disease related genes
  • Enzymes
  • FDA approved drug targets
  • Plasma proteins
  • Predicted intracellular proteins
  • Predicted membrane proteins
  • Predicted secreted proteins

Suggested Antigen Peptide Sequences for MET Gene

GenScript: Design optimal peptide antigens:
  • MET protein (A0PJF7_HUMAN)
  • Met proto-oncogene (Hepatocyte growth factor receptor), isoform CRA_c (A1L467_HUMAN)
  • cDNA FLJ51931, highly similar to Hepatocyte growth factor receptor (EC 2.7.10.1) (B4DPY6_HUMAN)
  • Soluble MET variant 1 (B5A929_HUMAN)
  • Soluble MET variant 2 (B5A930_HUMAN)

Graphical View of Domain Structure for InterPro Entry

P08581

UniProtKB/Swiss-Prot:

MET_HUMAN :
  • The kinase domain is involved in SPSB1 binding.
  • Belongs to the protein kinase superfamily. Tyr protein kinase family.
Domain:
  • The kinase domain is involved in SPSB1 binding.
  • The beta-propeller Sema domain mediates binding to HGF.
Family:
  • Belongs to the protein kinase superfamily. Tyr protein kinase family.
genes like me logo Genes that share domains with MET: view

Function for MET Gene

Molecular function for MET Gene

UniProtKB/Swiss-Prot Function:
Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During embryonic development, MET signaling plays a role in gastrulation, development and migration of muscles and neuronal precursors, angiogenesis and kidney formation. In adults, participates in wound healing as well as organ regeneration and tissue remodeling. Promotes also differentiation and proliferation of hematopoietic cells. May regulate cortical bone osteogenesis (By similarity).
UniProtKB/Swiss-Prot Function:
(Microbial infection) Acts as a receptor for Listeria monocytogenes internalin InlB, mediating entry of the pathogen into cells.
UniProtKB/Swiss-Prot CatalyticActivity:
Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-[protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1; Evidence=. ;.
UniProtKB/Swiss-Prot EnzymeRegulation:
In its inactive state, the C-terminal tail interacts with the catalytic domain and inhibits the kinase activity. Upon ligand binding, the C-terminal tail is displaced and becomes phosphorylated, thus increasing the kinase activity.
GENATLAS Biochemistry:
met proto-oncogene,transmembrane receptor (tyrosine kinase) for hepatocyte growth factor,with two alternatively spliced isoforms,important regulator of cell proliferation and differentiation,organ regeneration,embryogenesis and tumorogenesis,amplified in the glioblastomas,mutated in childhood hepatocellular carcinomas and hereditary papillary renal carcinomas (role in the acceleration of carcinogenesis),paralog to MST1R

Enzyme Numbers (IUBMB) for MET Gene

Phenotypes From GWAS Catalog for MET Gene

Gene Ontology (GO) - Molecular Function for MET Gene

GO ID Qualified GO term Evidence PubMed IDs
GO:0000166 nucleotide binding IEA --
GO:0004672 protein kinase activity IEA --
GO:0004713 protein tyrosine kinase activity TAS --
GO:0004714 transmembrane receptor protein tyrosine kinase activity IBA 21873635
GO:0005008 hepatocyte growth factor-activated receptor activity IBA 21873635
genes like me logo Genes that share ontologies with MET: view
genes like me logo Genes that share phenotypes with MET: view

Human Phenotype Ontology for MET Gene

HPO Id HPO Name Alternative Ids Definition Synonyms

Animal Models for MET Gene

MGI Knock Outs for MET:
  • Met Met<tm1Cbm>
  • Met Met<tm1.1Ics>
  • Met Met<tm1.1Sst>
  • Met Met<tm2.1Cbm>

Animal Model Products

CRISPR Products

Clone Products

  • Addgene plasmids for MET

No data available for Transcription Factor Targets and HOMER Transcription for MET Gene

Localization for MET Gene

Subcellular locations from UniProtKB/Swiss-Prot for MET Gene

Membrane; Single-pass type I membrane protein.
Isoform 3: Secreted.

Subcellular locations from

COMPARTMENTS
Extracellular space Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi Apparatus Nucleus Mitochondrion 0 1 2 3 4 5 Confidence
COMPARTMENTS Subcellular localization image for MET gene
Compartment Confidence
plasma membrane 5
extracellular 5
cytoskeleton 2
nucleus 2
endoplasmic reticulum 2
cytosol 2
mitochondrion 1
peroxisome 1
endosome 1
lysosome 1

Subcellular locations from the

Human Protein Atlas (HPA)
  • Cytosol (3)
  • Plasma membrane (3)
See all subcellular structures

Gene Ontology (GO) - Cellular Components for MET Gene

GO ID Qualified GO term Evidence PubMed IDs
GO:0005576 extracellular region IEA --
GO:0005886 plasma membrane TAS --
GO:0005887 integral component of plasma membrane TAS,IBA 21873635
GO:0009925 basal plasma membrane IDA 15314156
GO:0009986 cell surface HDA 19581412
genes like me logo Genes that share ontologies with MET: view

Pathways & Interactions for MET Gene

PathCards logo

SuperPathways for MET Gene

SuperPathway Contained pathways
1 RET signaling
2 Apoptotic Pathways in Synovial Fibroblasts
.85
.85
.84
.84
.74
.72
.66
.65
.62
.61
.60
.57
3 GPCR Pathway
.73
.73
.62
.59
.58
.58
.55
.38
4 PI3K/AKT activation
5 MET promotes cell motility
genes like me logo Genes that share pathways with MET: view

SIGNOR curated interactions for MET Gene

Activates:
Inactivates:
Is activated by:
Is inactivated by:

Gene Ontology (GO) - Biological Process for MET Gene

GO ID Qualified GO term Evidence PubMed IDs
GO:0000165 MAPK cascade TAS --
GO:0001886 endothelial cell morphogenesis IDA 14500721
GO:0001889 liver development IBA 21873635
GO:0006468 protein phosphorylation IEA --
GO:0006909 phagocytosis IBA 21873635
genes like me logo Genes that share ontologies with MET: view

Drugs & Compounds for MET Gene

(143) Drugs for MET Gene - From: DrugBank, PharmGKB, ClinicalTrials, ApexBio, DGIdb, IUPHAR, HMDB, Tocris, and Novoseek

Name Status Disease Links Group Role Mechanism of Action Clinical Trials
Crizotinib Approved Pharma Target, inhibitor, Inhibition, Biomarker C-MET/ALK inhibitor,potent and ATP-competitve, Potent c-MET/ALK inhibitor, cMET Inhibitors, Kinase Inhibitors, Anaplastic lymphoma kinase (ALK) inhibitor 125
cabozantinib Approved, Investigational Pharma Target, antagonist, inhibitor Kinase Inhibitors, Vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) inhibitors 0
Gefitinib Approved, Investigational Pharma EGFR Inhibitors, Kinase Inhibitors, Epidermal growth factor receptor (EGFR) inhibitors 397
Tyrosine Approved, Investigational Nutra 938
brigatinib Approved, Investigational Pharma Target, inhibitor 0

(33) Additional Compounds for MET Gene - From: HMDB, Novoseek, and Tocris

Name Synonyms Role CAS Number PubChem IDs PubMed IDs
ADP
  • 5'-Adenylphosphoric acid
  • Adenosine 5'-diphosphate
  • ADENOSINE-5'-diphosphATE
  • H3ADP
  • 5'-Adenylphosphate
Full agonist, Agonist, Partial agonist, Antagonist, Gating inhibitor 58-64-0
Norleual
334994-34-2
PF 04217903 mesylate
956906-93-7
SGX 523
1022150-57-7

(5) Tocris Compounds for MET Gene

Compound Action Cas Number
Norleual Highly potent HGF/c-MET inhibitor; also AT4 antagonist 334994-34-2
PF 04217903 mesylate Highly selective MET inhibitor 956906-93-7
PHA 665752 Potent and selective MET inhibitor 477575-56-7
SGX 523 Selective and potent c-MET kinase inhibitor 1022150-57-7
SU 11274 Selective inhibitor of MET kinase activity 658084-23-2

(33) ApexBio Compounds for MET Gene

Compound Action Cas Number
(R)-Crizotinib C-MET/ALK inhibitor,potent and ATP-competitve 877399-52-5
Altiratinib c-MET/TIE-2/VEGFR inhibitor 1345847-93-9
AMG-208 C-Met inhibitor,potent and highly selective 1002304-34-8
AMG-458 Potent c-Met inhibitor 913376-83-7
BMS-777607 C-Met inhibitor, potent and selective 1025720-94-8
BMS-794833 Met/VEGFR-2 inhibitor,potent and ATP-competitive 1174046-72-0
BMS-817378 Potent ATP competitive inhibitor of Met/VEGFR2 1174161-69-3
Cabozantinib (XL184, BMS-907351) VEGFR2/Met/Ret/Kit/FLT//AXL inhibitor 849217-68-1
Cabozantinib malate (XL184) MET andVEGF receptor2 inhibitor 1140909-48-3
c-Met inhibitor 1 Inhibitor of the c-Met receptor 1357072-61-7
EMD-1214063 C-Met inhibitor,potent and selective 1100598-32-0
Foretinib (GSK1363089) VEGF and HGF receptor inhibitor 849217-64-7
Golvatinib (E7050) C-Met/VEGFR-2 inhibitor 928037-13-2
INCB28060 C-Met inhibitor,ATP-competitive and novel 1029712-80-8
JNJ-38877605 C-Met inhibitor,ATP-competitive 943540-75-8
LY2801653 MET inhibitor 1206799-15-6
LY2801653 dihydrochloride MET inhibitor 1206801-37-7
MGCD-265 Met/Flt/Flk/Ron/Tie-2 inhibitor 875337-44-3
MK-2461 C-Met (WT/mutants) inhibitor 917879-39-1
MK-8033 C-MET inhibitor 1001917-37-8
MK-8033 hydrochloride C-Met/Ron inhibitor 1283000-43-0
NPS-1034 MET inhibitor 1221713-92-3
NVP-BVU972 C-Met inhibitor,potent and selective 1185763-69-2
PF-04217903 C-Met inhibitor,selective and ATP-competitive 956905-27-4
PF-04217903 methanesulfonate C-Met inhibitor,selective and ATP-competitive 956906-93-7
PHA-665752 C-Met inhibitor,potent and ATP-competitive 477575-56-7
SGX-523 MET inibitor, highly selective, ATP-competitive 1022150-57-7
SU11274 C-Met inhibitor,potent and selective 658084-23-2
SU5416 VEGF receptor inhibitor and AHR agonist 204005-46-9
TAE226 (NVP-TAE226) FAK inhibitor,potent and ATP-competitive 761437-28-9
Tivantinib (ARQ 197) C-Met inhibitor,non-ATP-competitive 905854-02-6
Tyrosine kinase inhibitor Tyrosine-kinase inhibitor 1021950-26-4
ZM 323881 HCl 193000-39-4
genes like me logo Genes that share compounds with MET: view

Drug Products

Transcripts for MET Gene

CRISPR Products

Clone Products

  • Addgene plasmids for MET

Alternative Splicing Database (ASD) splice patterns (SP) for MET Gene

ExUns: 1a · 1b ^ 2 ^ 3 ^ 4 ^ 5 ^ 6 ^ 7 ^ 8 ^ 9 ^ 10 ^ 11a · 11b ^ 12 ^ 13 ^ 14 ^ 15 ^ 16 ^ 17 ^ 18 ^ 19 ^ 20 ^ 21 ^ 22a · 22b
SP1: -
SP2: - -